Find Acetyldigitoxins manufacturers, exporters & distributors on PharmaCompass

Acetyldigitoxins

Acetyldigitoxins

Synopsis, Chemistry

DOSSIERs // Finished Dosage Formulations

1 Dossiers, 1 FDA Orange Book

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Alpha-acetyldigitoxin, 1111-39-3, Acylanid, Desglucolanatoside a, Acetyldiginatin, Acylanide

Molecular Formula

C₄₃H₆₆O₁₄

Molecular Weight

807.0 g/mol

InChI Key

HPMZBILYSWLILX-UMDUKNJSSA-N

FDA UNII

0ZV4Q4L2FU

Cardioactive derivatives of lanatoside A or of DIGITOXIN. They are used for fast digitalization in congestive heart failure.

1 2D Structure

Acetyldigitoxins

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate

2.1.2 InChI

InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1

2.1.3 InChI Key

HPMZBILYSWLILX-UMDUKNJSSA-N

2.1.4 Canonical SMILES

CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CCC7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O

2.1.5 Isomeric SMILES

C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O

2.2 Other Identifiers

2.2.1 UNII

0ZV4Q4L2FU

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Acedoxin

2. Acetyldigitoxins

3. Adicin

4. Alpha Acetyldigitoxin

5. Alpha-acetyldigitoxin

6. Desglucolanatosides A

7. Digitoxin Monoacetate

8. Monoacetate, Digitoxin

2.3.2 Depositor-Supplied Synonyms

1. Alpha-acetyldigitoxin

2. 1111-39-3

3. Acylanid

4. Desglucolanatoside A

5. Acetyldiginatin

6. Acylanide

7. Acetildigitoxina

8. Alpha-monoacetyldigitoxin

9. Acetyldigitoxinum

10. Acetyl-digitoxin-alpha

11. Acetylgitoxin

12. Digitoxin 3'''-acetate

13. Acetyldigitoxin [inn]

14. 3'''-o-acetyldigitoxin

15. Alpha-acetylgitaloxin

16. Acetyldigitoxin (inn)

17. 0zv4q4l2fu

18. Acetyldigitoxins .alpha.-form

19. Chebi:53773

20. (3beta,5beta)-3-((o-3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide

21. Acedigal

22. Adicin

23. [(2r,3r,4s,6s)-3-hydroxy-6-[(2r,3s,4s,6s)-4-hydroxy-6-[(2r,3s,4s,6r)-4-hydroxy-6-[[(3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] Acetate

24. Digitoxin, 3'''-acetate

25. Acylanid (tn)

26. Acetyldigitoxinum [inn-latin]

27. Alpha-acetyldigitoxins

28. Acetildigitoxina [inn-spanish]

29. Digitoxin, Alpha-acetyl-

30. Acetyldigitoxin [inn:nf]

31. Unii-0zv4q4l2fu

32. Acetyldigitoxins

33. Einecs 214-178-4

34. Brn 0077291

35. 3'''-acetyldigitoxin

36. Digitoxin, Acetate, Alpha-

37. Schembl309649

38. Gtpl6794

39. Acetyldigitoxin [mart.]

40. Acetyldigitoxin [who-dd]

41. Chembl3545057

42. Acetyldigitoxin [orange Book]

43. Zinc96006012

44. Db00511

45. (3beta,5beta)-3-((o-3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide

46. (3beta,5beta)-3-{[3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide

47. 3beta-[3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide

48. Hy-16022

49. Acetyldigitoxins .alpha.-form [mi]

50. Cs-0006116

51. C22191

52. D06881

53. (2r,3r,4s,6s)-3-hydroxy-6-{[(2r,3s,4s,6s)-4-hydroxy-6-{[(2r,3s,4s,6r)-4-hydroxy-6-{[(1s,2s,5s,7r,10r,11s,14r,15r)-11-hydroxy-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-2-methyloxan-4-yl Acetate

54. (3.beta.,5.beta.)-3-((o-3-o-acetyl-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide

55. Card-20(22)-enolide, 3-((o-3-o-acetyl-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-

2.4 Create Date

2005-11-20

3 Chemical and Physical Properties

Molecular Formula	C₄₃H₆₆O₁₄
Molecular Weight	807.0 g/mol
XLogP3	2.8
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	14
Rotatable Bond Count	9
Exact Mass	806.44525677 g/mol
Monoisotopic Mass	806.44525677 g/mol
Topological Polar Surface Area	189 Å²
Heavy Atom Count	57
Formal Charge	0
Complexity	1520
Isotope Atom Count	0
Defined Atom Stereocenter Count	20
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Used for fast digitalization in congestive heart failure.

5 Pharmacology and Biochemistry

5.1 Pharmacology

The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na⁺/K⁺ ATPase pump.

5.2 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

Cardiotonic Agents

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)

Anti-Arrhythmia Agents

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)

5.3 ATC Code

C - Cardiovascular system

C01 - Cardiac therapy

C01A - Cardiac glycosides

C01AA - Digitalis glycosides

C01AA01 - Acetyldigitoxin

5.4 Absorption, Distribution and Excretion

Absorption

Bioavailability is 60 to 80% following oral administration.

5.5 Mechanism of Action

Acetyldigitoxin binds to a site on the extracellular aspect of the α-subunit of the Na⁺/K⁺ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na⁺/K⁺ pump leads to increased Na⁺ levels, which in turn slows down the extrusion of Ca²⁺ via the Na⁺/Ca²⁺ exchange pump. Increased amounts of Ca²⁺ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias.